Combined cytotoxic and immune-stimulatory gene therapy for primary adult high-grade glioma: a phase 1, first-in-human trial-Reference-Cited by-同舟云学术

Combined cytotoxic and immune-stimulatory gene therapy for primary adult high-grade glioma: a phase 1, first-in-human trial

Published:2023-09 Issue:9 Volume:24 Page:1042-1052
ISSN:1470-2045
Container-title:The Lancet Oncology
language:en
Short-container-title:The Lancet Oncology

Author:

Umemura Yoshie,Orringer Daniel,Junck Larry,Varela Maria L,West Molly E J,Faisal Syed M,Comba Andrea,Heth Jason,Sagher Oren,Leung Denise,Mammoser Aaron,Hervey-Jumper Shawn,Zamler Daniel,Yadav Viveka N,Dunn Patrick,Al-Holou Wajd,Hollon Todd,Kim Michelle M,Wahl Daniel R,Camelo-Piragua Sandra,Lieberman Andrew P,Venneti Sriram,McKeever Paul,Lawrence Theodore,Kurokawa Ryo,Sagher Karen,Altshuler David,Zhao Lili,Muraszko Karin,Castro Maria G,Lowenstein Pedro R

Funder

Phase One Foundation

Cedars-Sinai Medical Center

University of Michigan

Rogel Cancer Center, University of Michigan

Publisher

Elsevier BV

Subject

Oncology

Reference32 articles.

1. The 2021 WHO classification of tumors of the central nervous system: a summary;Louis;Neuro-oncol,2021

2. Survival of patients with newly diagnosed glioblastoma treated with radiation and temozolomide in research studies in the United States;Grossman;Clin Cancer Res,2010